JP2014508784A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508784A5
JP2014508784A5 JP2014500216A JP2014500216A JP2014508784A5 JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5 JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5
Authority
JP
Japan
Prior art keywords
treatment
radiolabeled compound
cancer
radioactive imaging
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014500216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2012/000316 external-priority patent/WO2012129673A1/en
Publication of JP2014508784A publication Critical patent/JP2014508784A/ja
Publication of JP2014508784A5 publication Critical patent/JP2014508784A5/ja
Withdrawn legal-status Critical Current

Links

JP2014500216A 2011-03-25 2012-03-26 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤 Withdrawn JP2014508784A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467764P 2011-03-25 2011-03-25
US61/467,764 2011-03-25
PCT/CA2012/000316 WO2012129673A1 (en) 2011-03-25 2012-03-26 INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017253315A Division JP6727184B2 (ja) 2011-03-25 2017-12-28 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤

Publications (2)

Publication Number Publication Date
JP2014508784A JP2014508784A (ja) 2014-04-10
JP2014508784A5 true JP2014508784A5 (enExample) 2016-10-27

Family

ID=46929260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014500216A Withdrawn JP2014508784A (ja) 2011-03-25 2012-03-26 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤
JP2017253315A Expired - Fee Related JP6727184B2 (ja) 2011-03-25 2017-12-28 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017253315A Expired - Fee Related JP6727184B2 (ja) 2011-03-25 2017-12-28 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤

Country Status (6)

Country Link
US (1) US11072632B2 (enExample)
EP (1) EP2688901B1 (enExample)
JP (2) JP2014508784A (enExample)
AU (1) AU2012234682A1 (enExample)
CA (1) CA2830984C (enExample)
WO (1) WO2012129673A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207311A1 (en) * 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1
EP3013845B1 (en) * 2013-06-25 2020-03-18 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17b-hydroxysteroid dehydrogenase, type 1
WO2015169971A1 (en) * 2014-05-09 2015-11-12 Tangent Reprofiling Limited Modulators of androgen synthesis
EP3194419B1 (en) * 2014-09-11 2018-09-05 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
CZ307437B6 (cs) * 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EA201992826A1 (ru) * 2017-06-08 2020-05-14 Форендо Фарма Лтд 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
WO2024020520A2 (en) * 2022-07-20 2024-01-25 Board Of Regents, The University Of Texas System Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications
WO2025035212A1 (en) * 2023-08-15 2025-02-20 UNIVERSITé LAVAL Irreversible 17beta-hsd1 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP0309263B1 (en) * 1987-09-24 1994-03-09 Jencap Research Limited Hormone composition and use
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
US6933312B2 (en) * 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
BRPI0611623A2 (pt) * 2005-05-26 2010-09-21 Solvay Pharm Gmbh inibidores das 17beta-hsd1 e sts
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
MX2009002579A (es) * 2006-09-19 2009-03-20 Solvay Pharm Gmbh Derivados de estratrieno y sus usos como inhibidores de 17beta-hidroxiesteroide deshidrogenasa.
MX2009005201A (es) * 2006-11-30 2009-05-27 Solvay Pharm Gmbh Derivados de estratrieno sustituidos como inhibidores de 17beta hsd.
US20080171728A1 (en) 2007-01-12 2008-07-17 Quatrx Pharmaceuticals Co. Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
EP2014672A1 (en) * 2007-07-12 2009-01-14 Bayer Schering Pharma Aktiengesellschaft 8-beta-substituted estratrienes as selectively active estrogens

Similar Documents

Publication Publication Date Title
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
PL3725810T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego
HUS1900007I1 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
JP2014508784A5 (enExample)
IL235607A0 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EA201400178A1 (ru) Лечение рака молочной железы
LT3319993T (lt) Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
HUE043463T2 (hu) Vírusszerû részecske konjugátumok tumorok kezelésére
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
HRP20180670T1 (hr) Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
PL3053578T3 (pl) Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego
IL242546A0 (en) New compounds for cancer treatment
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft
LT2984108T (lt) Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei
SG11201506407VA (en) Kit for tumor imaging
IL245477B (en) Diagnosis of lung cancer
SG11201911602RA (en) 18f-labelled compound for prostate cancer diagnosis, and use thereof
AP2015008905A0 (en) Novel compounds for the treatment of cancer